Work

Why HbA1c remains the pragmatic choice for monitoring in India's public health system

Year: 2026

Type: article

Abstract: We read with interest the Viewpoint by Samajdar et al. regarding the limitations of HbA1c for monitoring diabetes in South Asia.1 While acknowledging the risk for misclassification, we contend that excluding HbA1c (glycated haemoglobin) from India's public healthcare system would exacerbate gaps in the diabetes care cascade by undermining diagnostic consistency and longitudinal monitoring for those seeking public care.

Source: The Lancet Regional Health - Southeast Asia

DOI: 10.1016/j.lansea.2026.100756

Authors: Joshua Chadwick, Ganeshkumar Parasuraman

Institution: National Institute of Epidemiology

Language: English

Topic: Diabetes Management and Research

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,250